| scholarly article | Q13442814 |
| P50 | author | Magdalena Kotańska | Q58658505 |
| Magdalena Jastrzębska-Więsek | Q59703080 | ||
| Joanna Sniecikowska | Q91350774 | ||
| Marcin Kolaczkowski | Q91350780 | ||
| Karolina Pytka | Q43191797 | ||
| P2860 | cites work | Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. | Q43497308 |
| Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. | Q43760124 | ||
| "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect | Q43959924 | ||
| Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma | Q44317525 | ||
| Pharmacological characterisation of the thermogenic effect of bupropion | Q45056272 | ||
| Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests. | Q46610840 | ||
| Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity | Q47324338 | ||
| Pica in rats is analogous to emesis: an animal model in emesis research | Q70519103 | ||
| Diabetic dyslipidaemia | Q89261937 | ||
| Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats | Q24675513 | ||
| Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter | Q26829749 | ||
| Dopamine signaling in food addiction: role of dopamine D2 receptors | Q27021853 | ||
| Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders | Q28260500 | ||
| 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists | Q28264695 | ||
| Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats | Q28275114 | ||
| A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity | Q28550518 | ||
| Brain dopamine and obesity | Q32040881 | ||
| Weight gain is associated with reduced striatal response to palatable food | Q34258063 | ||
| Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice | Q34547482 | ||
| Role of 5-HT3 receptor on food intake in fed and fasted mice | Q35196080 | ||
| The progression of cardiovascular risk to cardiovascular disease. | Q36970153 | ||
| Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors | Q37136276 | ||
| Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study | Q37189446 | ||
| Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. | Q37702373 | ||
| Targeting 5-HT receptors for the treatment of obesity | Q37844308 | ||
| Naltrexone/bupropion: an investigational combination for weight loss and maintenance. | Q37976220 | ||
| Serotonin controlling feeding and satiety | Q38248834 | ||
| Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit | Q38249884 | ||
| A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. | Q38298172 | ||
| Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats. | Q38298300 | ||
| Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice | Q38316225 | ||
| Therapeutic Potential of 5-HT6 Receptor Agonists. | Q38534316 | ||
| The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration. | Q42597841 | ||
| P304 | page(s) | 50 | |
| P577 | publication date | 2017-02-08 | |
| P1433 | published in | Frontiers in Neuroscience | Q2177807 |
| P1476 | title | Metabolic and Cardiovascular Benefits and Risks of EMD386088-A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor | |
| P478 | volume | 11 |
| Q91814012 | Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro |
| Q57039732 | Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT₆ Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo |
| Q47172455 | Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating. |
| Q91704575 | Social-housing and use of double-decker cages in rat telemetry studies |
| Q92128383 | The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment |
| Q88867837 | The histamine H3 receptor inverse agonist pitolisant reduces body weight in obese mice |
Search more.